Toronto, October 16, 2020 — Sigma Analytical Services announced that it has received its Good Manufacturing Practice (“GMP”) clearance from the Australian Therapeutic Goods Administration (“TGA”). The approval designates Sigma as an approved testing laboratory for Canadian companies to introduce their products into the Australian cannabis market. This ensures that all products tested by Sigma meet the highest regulatory standards in Australia under GMP.
“Sigma’s GMP approval in Australia is another milestone in our commitment to the safety and quality of products derived from cannabis,“ said Ashton Abrahams, Co-Founder and COO of Sigma. “As the legal cannabis sector continues to grow globally, we are excited to be at the forefront of testing and delivering cannabis products for medicinal and recreational purposes. Our GMP-certified services will now also bring extensive additional support to Canadian companies as they meet the regulations of the Australian market.”
The approval was granted by the TGA, the branch of the Australian Government’s Department of Health that regulates therapeutic goods such as prescription medicines and medical devices. The TGA is part of the Pharmaceutical Inspection Co-operation Scheme (PIC/S), an international body of regulatory authorities in the GMP field of medicinal products.
